BACKGROUND: Non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with initially unresected tumours represent a particular subset of patients with a poor outcome. Various international research groups pooled their data in a joint study in order to investigate prognostic variables and treatment modalities. METHODS: The study population consisted of 304 patients <21 years old treated between 1980 and 2005 using a multimodality therapeutic strategy. RESULTS: Synovial sarcoma and malignant peripheral nerve sheath tumour (MPNST) were the most frequent histotypes. Most patients received initial chemotherapy: major responses were recorded in 41% and minor in 16% of cases. Overall survival (OS) was 60.0% and 51.5% at 5 and 10 years, respectively, and it was significantly associated with patient's age, histological subtype, tumour site and size, quality of delayed surgical resection, radiotherapy administration and response to induction chemotherapy. MPNST associated to neurofibromatosis type 1 was the tumour type with the worst rate of response to chemotherapy and the worst outcome. CONCLUSIONS: In unresected NRSTS patients, radiotherapy and delayed surgery are of crucial importance. Patients who respond to chemotherapy have better chance of survival. However, given the relatively poor prognosis, research on intensive multimodal treatment approaches and novel strategies is warranted.
BACKGROUND:Non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with initially unresected tumours represent a particular subset of patients with a poor outcome. Various international research groups pooled their data in a joint study in order to investigate prognostic variables and treatment modalities. METHODS: The study population consisted of 304 patients <21 years old treated between 1980 and 2005 using a multimodality therapeutic strategy. RESULTS:Synovial sarcoma and malignant peripheral nerve sheath tumour (MPNST) were the most frequent histotypes. Most patients received initial chemotherapy: major responses were recorded in 41% and minor in 16% of cases. Overall survival (OS) was 60.0% and 51.5% at 5 and 10 years, respectively, and it was significantly associated with patient's age, histological subtype, tumour site and size, quality of delayed surgical resection, radiotherapy administration and response to induction chemotherapy. MPNST associated to neurofibromatosis type 1 was the tumour type with the worst rate of response to chemotherapy and the worst outcome. CONCLUSIONS: In unresected NRSTS patients, radiotherapy and delayed surgery are of crucial importance. Patients who respond to chemotherapy have better chance of survival. However, given the relatively poor prognosis, research on intensive multimodal treatment approaches and novel strategies is warranted.
Authors: A A Hayes-Jordan; S L Spunt; C A Poquette; A M Cain; B N Rao; A S Pappo; S J Shochat Journal: J Pediatr Surg Date: 2000-06 Impact factor: 2.545
Authors: Sheri L Spunt; D Ashley Hill; Alison M Motosue; Catherine A Billups; Alvida M Cain; Bhaskar N Rao; Charles B Pratt; Thomas E Merchant; Alberto S Pappo Journal: J Clin Oncol Date: 2002-08-01 Impact factor: 44.544
Authors: M Trojani; G Contesso; J M Coindre; J Rouesse; N B Bui; A de Mascarel; J F Goussot; M David; F Bonichon; C Lagarde Journal: Int J Cancer Date: 1984-01-15 Impact factor: 7.396
Authors: H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega Journal: Cancer Date: 1988-01-15 Impact factor: 6.860
Authors: Mehmet Fatih Okcu; Mark Munsell; Joern Treuner; Adrian Mattke; Alberto Pappo; Alvida Cain; Andrea Ferrari; Michela Casanova; Alp Ozkan; Beverly Raney Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: Thomas F DeLaney; Ira J Spiro; Herman D Suit; Mark C Gebhardt; Francis J Hornicek; Henry J Mankin; Andrew L Rosenberg; Daniel I Rosenthal; Fariba Miryousefi; Marcus Ancukiewicz; David C Harmon Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-15 Impact factor: 7.038
Authors: Rebecca D Dodd; Chang-Lung Lee; Tess Overton; Wesley Huang; William C Eward; Lixia Luo; Yan Ma; Davis R Ingram; Keila E Torres; Diana M Cardona; Alexander J Lazar; David G Kirsch Journal: Cancer Res Date: 2017-06-23 Impact factor: 12.701
Authors: Andrea Ferrari; Yueh-Yun Chi; Gian Luca De Salvo; Daniel Orbach; Bernadette Brennan; R Lor Randall; M Beth McCarville; Jennifer O Black; Rita Alaggio; Douglas S Hawkins; Gianni Bisogno; Sheri L Spunt Journal: Eur J Cancer Date: 2017-04-07 Impact factor: 9.162
Authors: Mohamad Farid; Elizabeth G Demicco; Roberto Garcia; Linda Ahn; Pamela R Merola; Angela Cioffi; Robert G Maki Journal: Oncologist Date: 2014-01-27
Authors: Lynn Million; Andrea Hayes-Jordan; Yueh-Yun Chi; Sarah S Donaldson; Suzanne Wolden; Carol Morris; Stephanie Terezakis; Fran Laurie; Karen Morano; T J Fitzgerald; Torunn I Yock; David A Rodeberg; James R Anderson; Rose Anne Speights; Jennifer O Black; Cheryl Coffin; Mary Beth McCarville; Simon C Kao; Douglas S Hawkins; Sheri L Spunt; R Lor Randall Journal: Int J Radiat Oncol Biol Phys Date: 2021-02-03 Impact factor: 8.013